Exact Sciences

The company said it plans to use the net proceeds for general corporate purposes, including for working capital and possible acquisitions.

The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.

The share prices of 20 companies in the 360Dx Index rose last month, with Exact Sciences, Natera, Invitae, and NeoGenomics the biggest gainers.

The company said test volume rose 87 percent to 186,000 during the quarter.

The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.

Armune, a University of Michigan spinout, owns licensing rights to protein biomarkers from the university for lung, breast, and prostate cancer.

Underwriter Merrill Lynch exercised in full the option to purchase up to an additional $90M in senior notes on top of a $600M notes offering announced last week.

Investors in Exact Sciences went on a selling spree after CellMax publicized data suggesting its test could outperform Cologuard for the early detection of colorectal cancer.

The company said it will use the proceeds from the offering for general corporate and working capital purposes.

Among the diagnostic firms presenting at the conference on Tuesday were lab giant LabCorp, diversified medical products firm Hologic, and MDx startups, such as Adaptive Biotechnologies.